Intra-Cellular Therapies, Inc.
NOVEL COMPOSITIONS AND METHODS

Abstract:

The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7- H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d.sub.2-3-methyl-2,3,6b,9,10,10a-he- xahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-o- ne or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d.sub.4-3-methyl-2,3,6b,9,10,10a- -hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-- 1-one, in free base, co-crystal or salt form, together with methods of making and using them.